The role of signal transduction in cancer treatment and drug resistance

被引:21
作者
Liem, AA
Chamberlain, MP
Wolf, CR
Thompson, AM [1 ]
机构
[1] Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland
[2] Univ Dundee, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland
[3] Univ Dundee, Biomed Res Ctr, Dundee DD1 9SY, Scotland
来源
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY | 2002年 / 28卷 / 06期
关键词
signal transduction; drug resistance; clinical trials; review;
D O I
10.1053/ejso.2002.1303
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Drug resistance in the treatment of cancer still remains a major clinical challenge, in part due to an insufficient understanding of the pathways by which these drugs interact with the mechanisms underlying cellular behaviour and cancer pathogenesis. Signal transduction involves cell differentiation, proliferation and cell death with alterations in these mechanisms being involved in the pathogenesis of cancer. It has been postulated that such pathways could be linked to anti-cancer drug resistance. Recently, novel approaches to overcome anti-cancer drug resistance through manipulation of signal transduction pathways, have been introduced in clinical trials. In this article we present a review of the current understanding in the field of signal transduction and the existing evidence for its role in drug resistance. We also discuss its clinical relevance with regard to overcoming drug resistance. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:679 / 684
页数:6
相关论文
共 84 条
  • [1] AFTAB DT, 1994, ONCOL RES, V6, P59
  • [2] Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53
    Bacus, SS
    Gudkov, AV
    Lowe, M
    Lyass, L
    Yung, Y
    Komarov, AP
    Keyomarsi, K
    Yarden, Y
    Seger, R
    [J]. ONCOGENE, 2001, 20 (02) : 147 - 155
  • [3] Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer
    Baekelandt, M
    Lehne, G
    Tropé, CG
    Szántó, I
    Pfeiffer, P
    Gustavssson, B
    Kristensen, GB
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (12) : 2983 - 2993
  • [4] Molecular targets for breast cancer therapy and prevention
    Bange, J
    Zwick, E
    Ullrich, A
    [J]. NATURE MEDICINE, 2001, 7 (05) : 548 - 552
  • [5] Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein
    Benderra, Z
    Trussardi, A
    Morjani, H
    Villa, AM
    Doglia, SM
    Manfait, M
    [J]. EUROPEAN JOURNAL OF CANCER, 2000, 36 (03) : 428 - 434
  • [6] Oncogenic kinase signalling
    Blume-Jensen, P
    Hunter, T
    [J]. NATURE, 2001, 411 (6835) : 355 - 365
  • [7] The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44(MAPK) cascade
    Brondello, JM
    Brunet, A
    Pouyssegur, J
    McKenzie, FR
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (02) : 1368 - 1376
  • [8] Cancer research 2000: drug resistance, new targets and drugs in development
    Broxtermon, HJ
    Georgopapadakou, N
    [J]. DRUG RESISTANCE UPDATES, 2000, 3 (03) : 133 - 138
  • [9] Co-ordinate loss of protein kinase C and multidrug resistance gene expression in revertant MCF-7/Adr breast carcinoma cells
    Budworth, J
    Gant, TW
    Gescher, A
    [J]. BRITISH JOURNAL OF CANCER, 1997, 75 (09) : 1330 - 1335
  • [10] Novel anticancer drug discovery
    Buolamwini, JK
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 1999, 3 (04) : 500 - 509